[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Sobieraj DM, Wang F, Kirton OC: Warfarin resistance after total gastrectomy and Roux-en-Y esophagojejunostomy. Pharmacotherapy; 2008 Dec;28(12):1537-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nutritional deficiencies due to malabsorption occur after major gastric resection, and drugs that are primarily absorbed in the stomach or duodenum also are likely to exhibit decreased absorption.
  • However, we performed a MEDLINE search (1960-2007) and found no evidence in the literature regarding the specific effects of warfarin absorption after total gastrectomy with Roux-en-Y gastric bypass procedure.
  • We describe a 71-year-old woman receiving warfarin therapy for chronic atrial fibrillation who underwent a completion gastrectomy and Roux-en-Y esophagojejunostomy for an invasive adenocarcinoma of her gastric remnant.
  • At the time of her admission for the surgery, however, her INR was subtherapeutic at 1.73; warfarin was discontinued, and heparin and, subsequently, enoxaparin were used throughout her admission.
  • After the surgery, the patient was discharged to a skilled nursing facility to continue bridge therapy with enoxaparin while warfarin was restarted and adjusted to a therapeutic INR of 2-3.
  • Three months after discharge, the patient was hospitalized again for shortness of breath and was found to have an INR of 1.30 on admission, despite good compliance with her drugs.
  • During this admission, the patient demonstrated resistance to warfarin therapy, requiring doses up to 20 mg/day to reach a therapeutic INR.
  • To our knowledge, this is the first case report to demonstrate that patients undergoing a complete gastric resection followed by a Roux-en-Y gastric bypass procedure may display warfarin resistance.
  • Close monitoring and dosage adjustment may be necessary to maintain therapeutic anticoagulation in these patients.
  • [MeSH-major] Drug Resistance. Gastrectomy / methods. Gastric Bypass / methods. Warfarin / therapeutic use
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Atrial Fibrillation / diagnosis. Atrial Fibrillation / drug therapy. Chronic Disease. Esophagus / surgery. Female. Humans. International Normalized Ratio / statistics & numerical data. Jejunum / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19025435.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5Q7ZVV76EI / Warfarin
  •  go-up   go-down


2. Nitta Y, Nishibori M, Iwagaki H, Yoshino T, Mori S, Sawada K, Nakaya N, Saeki K, Tanaka N: Changes in serotonin dynamics in the gastrointestinal tract of colon-26 tumour-bearing mice: effects of cisplatin treatment. Naunyn Schmiedebergs Arch Pharmacol; 2001 Oct;364(4):329-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in serotonin dynamics in the gastrointestinal tract of colon-26 tumour-bearing mice: effects of cisplatin treatment.
  • Severe nausea and vomiting are common side effects of anti-cancer chemotherapy.
  • 5-HT3 receptor antagonists have been used for the treatment of these gastrointestinal symptoms.
  • The purpose of this study was to examine whether specific changes in serotonin dynamics occurred in the gastrointestinal tract in mice in which Colon-26 adenocarcinoma cells were injected s.c., especially after treatment with cisplatin.
  • The serotonin content of the small intestine of mice inoculated s.c. with Colon-26 adenocarcinoma increased significantly 2 weeks after the inoculation of the tumor cells; this was associated with an increase in tryptophan hydroxylase activity and the number of enterochromaffin cells as compared with control mice.
  • The spontaneous release of serotonin from isolated intestine was not different between Colon-26 tumour-bearing and control mice; however, pretreatment of mice with cisplatin induced two fold increases in serotonin release from duodenum, jejunum and ileum in Colon-26 tumour-bearing mice but not in control mice.
  • Cisplatin treatment induced the release of serotonin from affected enterochromaffin cells in the gastrointestinal tract, which may be related to the occurrence of nausea in clinical use.
  • [MeSH-minor] Animals. Cell Count. Cell Division / drug effects. Enterochromaffin Cells / drug effects. Immunohistochemistry. Male. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Tryptophan Hydroxylase / metabolism. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11683520.001).
  • [ISSN] 0028-1298
  • [Journal-full-title] Naunyn-Schmiedeberg's archives of pharmacology
  • [ISO-abbreviation] Naunyn Schmiedebergs Arch. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 333DO1RDJY / Serotonin; EC 1.14.16.4 / Tryptophan Hydroxylase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Kini S, Kapadia RM, Amarapurkar A: Intussusception due to intestinal metastasis from lung cancer. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):141-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A computerized tomography (CT)--scan abdomen showed mural thickening of short loop of jejunum with ileoileal intussusception.
  • The patient, a diagnosed case of primary carcinoma of lung seven months ago, had been treated with one cycle of chemotherapy.
  • Histopathology of the small intestinal nodules showed features of adenocarcinoma consistent with the known primary lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ileal Neoplasms / complications. Ileal Neoplasms / secondary. Intussusception / diagnosis. Intussusception / pathology. Lung Neoplasms / complications. Lung Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090247.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. Kobayashi K, Yano S, Kato K, Tatsukawa T, Ikeda T, Tokushima T: [Case with double primary cancers occurring synchronously in both the lung and jejunum diagnosed according to TTF-1 expression]. Nihon Kokyuki Gakkai Zasshi; 2005 Feb;43(2):84-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case with double primary cancers occurring synchronously in both the lung and jejunum diagnosed according to TTF-1 expression].
  • A 47-year-old man was diagnosed as having adenocarcinoma of the lung (T4N0M0) in August 2002.
  • He received chemotherapy and radiotherapy.
  • The lymph node was near by the Treitz' ligament, and a tumor measuring 30 mm was observed in the jejunum.
  • Pathological examination of the lesion demonstrated adenocarcinoma.
  • As adenocarcinoma of the jejunum was negative for TTF-1 in immunohistochemical staining and adenocarcinoma of the lung was positive, we diagnosed this patient as having primary jejunal cancer.
  • We report this rare case of double cancer involving the lung and jejunum.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Intestine, Small. Jejunal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Nuclear Proteins / analysis. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770938.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


5. Ogata Y, Yamaguchi K, Sasatomi T, Uchida S, Akagi Y, Shirouzu K: [Treatment and outcome in small bowel cancer]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1454-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and outcome in small bowel cancer].
  • In adenocarcinoma of the small intestine, delays in diagnosis are frequent, and the majority of patients present with advanced- stage disease and either lymph node involvement or distant metastatic disease.
  • Surgical resection is a mainstay in treatment of this disease, but the role of adjuvant therapy is unclear.
  • Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma.
  • Further clinical studies on this rare type of tumor are needed.
  • The 72nd Japanese Society for Cancer of the Colon and Rectum have conducted a retrospective review of Japanese patients with adenocarcinoma of the jejunum or ileum.
  • The data indicated that although not statistically significant, there was a trend in median overall survival favoring the chemotherapy for advanced jejunal or ileal adenocarcinoma (17 months vs. 8 months, p=0.114).
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy. Intestine, Small
  • [MeSH-minor] Combined Modality Therapy. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716869.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


6. Saito N, Ohata M, Ishii H, Ohori M, Tokura Y, Maruyama M, Furukawa T, Sato H: [A case of unresectable colon cancer responding to oral leucovorin+oral tegafur/uracil]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was a 63-year-old man,who first visited our hospital with the chief complaints of left lower quadrant pain and abdominal distension that had developed around November 13, 2004.
  • Intraoperatively, the sigmoid colon was firmly fixed to the retroperitonium, there was a hard node in the pouch of Douglas, and that part of the jejunum was involved.
  • After the surgery,the patient was treated with 4 courses of therapy with oral Leucovorin (LV, 75 mg) +oral tegafur/uracil (UFT, 400 mg).
  • This time it was relatively easy to free the sigmoid colon.
  • The patient made good progress after the operation and was discharged on the 11 th POD.
  • At present he is receiving chemotherapy with UFT+oral LV as an outpatient.
  • As this therapy is relatively easy to perform and imposes only a small burden on patients,we think that it may be effective not only as adjuvant chemotherapy but also as neoadjuvant chemotherapy in some patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colon, Sigmoid / surgery. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Sigmoid Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Combined Modality Therapy. Drug Administration Routes. Drug Combinations. Gastric Bypass. Hepatectomy. Humans. Jejunum / surgery. Leucovorin / administration & dosage. Male. Middle Aged. Neoadjuvant Therapy. Palliative Care. Second-Look Surgery. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687215.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin
  •  go-up   go-down


7. van Lieshout AP, van Hillegersberg R, Richel DJ, van Slooten HJ, van Lanschot JJ: [Primary adenocarcinoma of the small intestine]. Ned Tijdschr Geneeskd; 2003 Nov 1;147(44):2149-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the small intestine].
  • A laparotomic partial resection of the affected jejunum and corresponding mesentery was performed.
  • A primary adenocarcinoma of the small intestine was diagnosed; pathology revealed that the resections were radical, and pT3N0, pT2N0 and pT3N0 stage tumours respectively.
  • In the third patient, liver and peritoneal metastases developed 16 months after surgery; he died 10 months after palliative chemotherapy had been initiated.
  • Adenocarcinoma of the small intestine is a rare disease and patients often present late with aspecific complaints.
  • Surgery is the only curative treatment currently available.
  • A greater awareness of this type of tumour is needed for treatment results to improve.
  • [MeSH-major] Adenocarcinoma / diagnosis. Intestinal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2004 Apr 17;148(16):802-3; author reply 803 [15129573.001]
  • (PMID = 14626829.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Hölscher AH, Vallböhmer D: [Surgical treatment of esophageal tumors including local ablation]. Zentralbl Chir; 2007 Apr;132(2):W18-36; quiz W37-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of esophageal tumors including local ablation].
  • [Transliterated title] Chirurgische Therapie von Osophagustumoren einschliesslich lokaler Ablation.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / radiotherapy. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Esophagectomy. Humans. Jejunum / transplantation. Leiomyosarcoma / drug therapy. Leiomyosarcoma / pathology. Leiomyosarcoma / radiotherapy. Leiomyosarcoma / surgery. Lymph Node Excision. Melanoma / drug therapy. Melanoma / pathology. Melanoma / radiotherapy. Melanoma / surgery. Neoadjuvant Therapy. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17516311.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Okita A, Miyade Y, Okano K: Effective management of an advanced gastric cancer patient by TS-1 combined chemotherapy using nasojejunal tube and successful transfer to home care after percutaneous transesophageal gastro-tubing (PTEG): a case report. Acta Med Okayama; 2010 Feb;64(1):67-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective management of an advanced gastric cancer patient by TS-1 combined chemotherapy using nasojejunal tube and successful transfer to home care after percutaneous transesophageal gastro-tubing (PTEG): a case report.
  • After successful nasojejunal tube feeding because of oral intake disability, TS-1 combined with paclitaxel chemotherapy was selected.
  • After the fifth cycle, she was transferred to her home and received chemotherapy in an outpatient clinic.
  • PTEG was useful not only for a route of TS-1 administration, but also for receiving chemotherapy at home to maintain her quality.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Gastrostomy / methods. Intubation, Gastrointestinal / methods. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Fatal Outcome. Female. Humans. Jejunum. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Severity of Illness Index. Tegafur / administration & dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20200587.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Pinocy J, Klotz M, Weinzierl B, Schunck R, Weber P: [Primary adenocarcinoma of the jejunum. Diagnostic challenge by a rare tumour]. Dtsch Med Wochenschr; 2008 May;133(20):1064-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the jejunum. Diagnostic challenge by a rare tumour].
  • [Transliterated title] Primäres Adenokarzinom des Dünndarms. Diagnostische Herausforderung durch eine seltene Tumorentität.
  • INVESTIGATIONS: The source of nausea and vomiting had been achieved by double contrast enteroclysis in the upper jejunum and it was confirmed with a coloskop.
  • TREATMENT AND COURSE: Histological result was a primary small bowel adenocarcinoma.
  • The primary definitive therapy was a radical resection of the jejunal neoplastic loop, also as an important prognostic factor.
  • Because of the tumour stadium adjuvant chemotherapy was not necessary.
  • With the help of an primary small bowel adenocarcinoma we suggest an algorithm of diagnostic possibilities adjusted to the clinical situation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Jejunal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Algorithms. Colonoscopy. Constriction, Pathologic / etiology. Humans. Jejunum / pathology. Jejunum / radiography. Male. Nausea. Neoplasm Staging. Prognosis. Vomiting

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18461524.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Kim HK, Ko BM, Park JK, Hong SJ, Moon JH, Lee JS, Lee MS, Kim BS: [A case of locally invasive obstructive jejunal cancer with curative resection after stenting and chemotherapy]. Korean J Gastroenterol; 2010 Jul;56(1):54-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of locally invasive obstructive jejunal cancer with curative resection after stenting and chemotherapy].
  • Small bowel adenocarcinoma is a relatively rare malignancy.
  • In Korea, 13.1% of small bowel adenocarcinoma occurs in the jejunum.
  • The absence of effective screening methods and relatively obscure symptoms contribute to the higher percentage of advanced cases at the time of diagnosis.
  • Although curative resection is the mainstay of treatment, it is often impossible.
  • Chemotherapy and radiotherapy have shown a disappointing treatment result for advanced staged small bowel adenocarcinoma.
  • We report a 54-year-old woman with locally invasive jejunal cancer who underwent curative resection after stent insertion with enteroscopy and chemotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Intestinal Obstruction / diagnosis. Jejunal Neoplasms / diagnosis. Stents
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Endoscopy, Gastrointestinal. Female. Fluorouracil. Humans. Leucovorin. Middle Aged. Organoplatinum Compounds. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664318.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


12. Murphy JO, Ravi N, Byrne PJ, McDonald GS, Reynolds JV: Neither antioxidants nor COX-2 inhibition protect against esophageal inflammation in an experimental model of severe reflux. J Surg Res; 2007 Sep;142(1):20-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Reflux-induced injury and oxidative stress result in esophageal inflammation and the potential for progression to intestinal metaplasia and adenocarcinoma.
  • Proton-pump inhibitors represent the standard medical approach, but anti-inflammatories and antioxidants offer novel therapeutic possibilities.
  • MATERIALS AND METHODS: Six weeks after an esophagojejunostomy reflux procedure, female Wistar rats (n = 100) were randomized to receive either an antioxidant (vitamin C, 8 mg or 28 mg/day), a cyclooxygenase-2 (COX-2) inhibitor (rofecoxib, 1 mg/day), or no therapy.
  • No animal developed metaplasia or tumor.
  • [MeSH-major] Antioxidants / therapeutic use. Ascorbic Acid / therapeutic use. Cyclooxygenase 2 Inhibitors / therapeutic use. Esophagitis, Peptic / prevention & control. Lactones / therapeutic use. Sulfones / therapeutic use
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Esophagus / pathology. Esophagus / surgery. Female. Inflammation / pathology. Inflammation / prevention & control. Jejunum / pathology. Jejunum / surgery. Models, Animal. Random Allocation. Rats. Rats, Wistar. Ulcer / pathology. Ulcer / prevention & control

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17543990.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Cyclooxygenase 2 Inhibitors; 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


13. Nozawa H, Yamada Y, Muto Y, Endo J, Asakage M, Oka T, Furukawa Y, Arai M: Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report. Eur J Gastroenterol Hepatol; 2010 Feb;22(2):228-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report.
  • We report a male patient with double advanced tumors in the jejunum and descending colon and multiple lung tumors.
  • Biopsied lung tumor was diagnosed as tubular adenocarcinoma, and CK7(+)/CK20(+)/Cdx-2(-).
  • Together with clinical information, we deduced that the jejunal adenocarcinoma had presumably metastasized to the lung.
  • Moreover, postoperative oxaliplatin, including chemotherapy, significantly reduced the lung metastases, suggesting that this regimen is a promising treatment option for advanced small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Colonic Neoplasms / pathology. Immunohistochemistry. Jejunal Neoplasms / pathology. Lung Neoplasms / secondary. Neoplasms, Multiple Primary
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Colectomy. Fatal Outcome. Fluorouracil / therapeutic use. Homeodomain Proteins / analysis. Humans. Keratin-20 / analysis. Keratin-7 / analysis. Leucovorin / therapeutic use. Lymph Node Excision. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / therapeutic use. Phenotype. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19923997.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


14. Murphy JO, Ravi N, Byrne PJ, McDonald GS, Reynolds JV: Neither antioxidants nor COX-2 inhibition protect against esophageal inflammation in an experimental model of severe reflux. J Surg Res; 2008 Mar;145(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Reflux-induced injury and oxidative stress result in esophageal inflammation and the potential for progression to intestinal metaplasia and adenocarcinoma.
  • Proton-pump inhibitors represent the standard medical approach, but anti-inflammatories and antioxidants offer novel therapeutic possibilities.
  • MATERIALS AND METHODS: Six weeks after an esophagojejunostomy reflux procedure, female Wistar rats (n = 100) were randomized to receive either an antioxidant (vitamin C, 8 mg or 28 mg/day), a cyclooxygenase-2 (COX-2) inhibitor (rofecoxib, 1 mg/day), or no therapy.
  • No animal developed metaplasia or tumor.
  • [MeSH-major] Antioxidants / therapeutic use. Cyclooxygenase 2 Inhibitors / therapeutic use. Esophagitis, Peptic / prevention & control
  • [MeSH-minor] Animals. Ascorbic Acid / therapeutic use. Disease Models, Animal. Dose-Response Relationship, Drug. Esophagus / pathology. Esophagus / surgery. Female. Jejunum / surgery. Lactones / therapeutic use. Random Allocation. Rats. Rats, Wistar. Sulfones / therapeutic use

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727884.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Cyclooxygenase 2 Inhibitors; 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


15. Innis M, Sandiford N, Shenoy RK, Prussia PR, Zbar A: Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy. West Indian Med J; 2005 Sep;54(4):242-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy.
  • Jejunal adenocarcinoma is rare, often presenting late with widespread intraperitoneal disease.
  • Intraperitoneal chemotherapy (IPC) has been shown in non-randomized studies to improve the survival of patients presenting with intraperitoneal metastases from carcinoma of the colon, appendix and stomach and in primary peritoneal malignancies including mesothelioma and pseudomyxoma peritonei, providing that adequate operative cytoreduction can be performed.
  • A case is presented of obstructive jejunal adenocarcinoma in which 19 intraperitoneal deposits were excised.
  • The patient was treated successfully with immediate postoperative IPC followed by systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols. Jejunal Neoplasms / drug therapy. Jejunal Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16312191.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Jamaica
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Bowen JM, Gibson RJ, Cummins AG, Tyskin A, Keefe DM: Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemother Pharmacol; 2007 Feb;59(3):337-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is the first investigation using microarray to assess chemotherapy-induced changes in the gut.
  • Jejunal tissue was harvested and RNA was isolated. cDNA was synthesised and purified, prior to hybridisation and microarray analysis.
  • In particular, multiple genes implicated in the mitogen-activated protein kinase (MAPK) signalling pathway were differentially regulated following treatment.
  • RT-PCR was used to confirm effects of irinotecan on caspase-1 expression in jejunal tissue and was significantly increased 6 h after treatment with irinotecan.
  • The common pathway of chemotherapy- and radiotherapy-induced damage, which utilises the caspase-cascade, may be a useful target to prevent apoptosis following cancer treatment.
  • [MeSH-major] Adenocarcinoma / genetics. Antineoplastic Agents, Phytogenic / pharmacology. Camptothecin / analogs & derivatives. Gene Expression Regulation, Neoplastic / drug effects. Jejunum / drug effects. Mammary Neoplasms, Experimental / genetics
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / genetics. Caspase 1 / genetics. Caspase 1 / metabolism. Down-Regulation / drug effects. Female. Mitogen-Activated Protein Kinase Kinases / genetics. Mitogen-Activated Protein Kinase Kinases / metabolism. Mucositis / chemically induced. Mucositis / genetics. Mucositis / pathology. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis. RNA, Messenger / metabolism. Rats. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation / drug effects

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799812.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / RNA, Messenger; 7673326042 / irinotecan; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.4.22.36 / Caspase 1; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


17. Gibson RJ, Keefe DM, Thompson FM, Clarke JM, Goland GJ, Cummins AG: Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci; 2002 Dec;47(12):2751-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats.
  • Gastrointestinal mucositis after cancer chemotherapy is an increasing problem that is essentially untreatable once established, although it gradually remits.
  • The aim of this study was to investigate the time-course and effect of interleukin-11 (IL-11) on apoptosis and intestinal morphometry as measures of mucositis.
  • Apoptosis was assessed by TUNEL assay in the tumor and jejunum.
  • The time-course study showed that MTX increased apoptosis by 28-fold in the crypts of the small intestine and by 3-fold in the tumor, and peaked at 6 hr after chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / adverse effects. Breast Neoplasms / drug therapy. Interleukin-11 / pharmacology. Interleukin-11 / therapeutic use. Intestinal Mucosa / drug effects. Methotrexate / adverse effects
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Division / drug effects. Female. Organ Size. Rats. Rats, Inbred Strains

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1962 Mar;42:295-305 [13922473.001]
  • [Cites] Stem Cells. 1994;12 Suppl 1:79-89; discussion 89-90 [7696971.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5453-65 [9850079.001]
  • [Cites] Oncologist. 1998;3(6):446-451 [10388137.001]
  • [Cites] Br J Cancer Suppl. 1986;7:20-2 [3459520.001]
  • [Cites] Stem Cells. 1997;15(2):82-93 [9090784.001]
  • [Cites] Comput Biol Med. 1984;14(4):437-45 [6548944.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2023-30 [7512836.001]
  • [Cites] Gut. 2000 Nov;47(5):632-7 [11034578.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):585-93 [8637716.001]
  • [Cites] Clin Sci (Lond). 1997 Apr;92(4):385-9 [9176038.001]
  • [Cites] J Endocrinol. 2001 Jun;169(3):539-47 [11375124.001]
  • [Cites] Cell Prolif. 1995 Nov;28(11):581-94 [8555371.001]
  • [Cites] Cancer Metastasis Rev. 1992 Sep;11(2):179-95 [1394796.001]
  • [Cites] Exp Hematol. 1996 Sep;24(11):1289-97 [8862439.001]
  • [Cites] Gastroenterology. 1962 Oct;43:407-24 [13994153.001]
  • [Cites] Int J Cancer. 1995 Jul 28;62(3):356-61 [7628879.001]
  • [Cites] Br J Cancer. 1983 Feb;47(2):175-85 [6824565.001]
  • [Cites] Gut. 1990 Mar;31(3):317-21 [2323596.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] Lab Invest. 1996 Jul;75(1):33-42 [8683938.001]
  • [Cites] EMBO J. 1994 Oct 17;13(20):4765-75 [7957045.001]
  • [Cites] Stem Cells. 1996 Jul;14(4):452-9 [8843547.001]
  • [Cites] Br J Cancer. 1987 Feb;55(2):113-23 [3814484.001]
  • (PMID = 12498296.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Interleukin-11; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Gibson RJ, Keefe DM, Clarke JM, Regester GO, Thompson FM, Goland GJ, Edwards BG, Cummins AG: The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol; 2002 Jul;50(1):53-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer.
  • PURPOSE: Mucositis from cancer chemotherapy is a common problem for which there is no definitive treatment.
  • Prevention and successful treatment could significantly enhance the quality of life of patients, and improve survival; however any potential preventative agent must not enhance tumour growth.
  • METHODS: Tumour-bearing rats received KGF or saline for 5 days prior to either MTX or saline treatment, and were killed 24 h after the last MTX injection.
  • Apoptosis was assessed by TUNEL assay in the tumour and jejunum.
  • RESULTS: KGF increased the weight of the small intestine prior to chemotherapy but the weight was not maintained after chemotherapy.
  • CONCLUSIONS: We conclude that KGF had a modest effect on intestinal growth prior to chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Enteritis / drug therapy. Fibroblast Growth Factors / therapeutic use. Intestinal Mucosa / drug effects. Mammary Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Antimetabolites, Antineoplastic / adverse effects. Cell Division / drug effects. DNA, Neoplasm / drug effects. Female. Fibroblast Growth Factor 7. In Situ Nick-End Labeling. Keratinocytes / metabolism. Methotrexate / adverse effects. Rats. Recombinant Proteins / pharmacology. Recombinant Proteins / therapeutic use. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12111112.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA, Neoplasm; 0 / Fgf7 protein, rat; 0 / Recombinant Proteins; 126469-10-1 / Fibroblast Growth Factor 7; 62031-54-3 / Fibroblast Growth Factors; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


19. Aoki Y, Kameda A, Miyahara E, Funakoshi M: [A patient with small intestinal cancer and extensive lymph node metastasis who responded to S-1]. Gan To Kagaku Ryoho; 2010 May;37(5):927-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upper digestive tract endoscopy revealed a flat plate-like ulcer in the jejunum on the anal side of the gastrojejunostomy site.
  • Biopsy findings suggested undifferentiated adenocarcinoma.
  • Computed tomography (CT) showed cervical, mediastinal, and intraperitoneal lymph node swelling, suggesting metastasis.
  • Therefore, surgery was not performed, and systemic hemotherapy with S-1 (80 mg/body/day) was administered.
  • During the 7-month follow-up after the initial consultation (7 courses of S-1 therapy in all), there has been no exacerbation, and the quality of life (QOL) has been maintained.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / pathology. Intestine, Small / pathology. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Biopsy. Drug Combinations. Endoscopy, Gastrointestinal. Humans. Lymphatic Metastasis. Male. Quality of Life. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495331.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


20. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA: Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer; 2008 Oct 15;113(8):2038-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
  • BACKGROUND: Metastatic small bowel adenocarcinoma (SBA) has a poor prognosis.
  • Because of the rarity of SBA, only a few studies have evaluated the role of chemotherapy in the treatment of metastatic SBA; thus, the benefit, if any, of adding a platinum compound to fluorouracil (5-FU) is unknown.
  • The objective of this retrospective study was to determine whether the addition of a platinum compound to 5-FU provided any benefit in the treatment of patients with metastatic SBA.
  • METHODS: The authors identified 80 patients with metastatic SBA who were treated with chemotherapy at the University of Texas M. D.
  • Response rates, progression-free survival (PFS), and overall survival (OS) were compared between patients who received 5-FU and a platinum compound and patients who received other chemotherapy combinations.
  • The primary tumor site was the jejunum in 35 patients (43%), duodenum in 30 patients (38%), ileum in 6 patients (8%), and nonspecified small bowel in 9 patients (11%).
  • Of all 80 patients, 29 patients (36%) received 5-FU and a platinum compound, 41 patients (51%) received 5-FU without a platinum compound, and 10 patients (13%) received non-5-FU-based treatment.
  • Compared with other chemotherapy regimens, treatment with 5-FU and a platinum agent resulted in a higher response rate (46% vs 16% with other regimens; P = .01) and longer median PFS (8.7 months vs 3.9 months; P < or = .01) but not better OS (14.8 months vs 12 months; P = .1).
  • In multivariate analysis, treatment with 5-FU and a platinum compound was a significant predictor of response (odds ratio, 4.5; 95% confidence interval [CI], 1.3-15.8; P = .02) and PFS (hazard ratio.
  • CONCLUSIONS: To the authors' knowledge, the current analysis represents the largest number of patients with metastatic SBA treated with chemotherapy in the literature, and the results suggested that the combination of 5-FU and a platinum compound leads to a higher response rate and PFS compared with other chemotherapy regimes.
  • The authors concluded that prospective investigation of platinum analogues in the treatment of SBA is warranted.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Platinum Compounds / administration & dosage. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18759326.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platinum Compounds; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Sugae T, Yaguchi T, Kajikawa M, Nakayama S, Takase T, Inokawa Y, Tsushima Y, Watanabe T, Harada A: [A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1969-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX].
  • This is an account of a case of primary adenocarcinoma of the small intestine successfully treated with chemotherapy.
  • Abdominal computerized tomography revealed bowel obstruction, and this was found at surgery to be due to a tumor at the jejunum 100 cm distal from the Treitz ligament.
  • Pathological diagnosis of the resected specimen was adenocarcinoma.
  • Although adjuvant chemotherapy with doxifluridine 800 mg/day was given, a recurrent lesion at the abdominal wall was detected 19 months after surgery.
  • It was not long before another recurrence developed at the abdominal wall with a subsequent rise in tumor markers. mFOLFOX6 (oxaliplatin 85 mg/m2, levofolinate calcium 200 mg/m2, 5-FU 400/2,400 mg/m2) was given, and the patient responded.
  • Primary small intestinal adenocarcinoma is a rare disease with a dismal prognosis.
  • Due to rarity of the disease, clinical trials have not been performed, and little is known about the effect of chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / pathology. Intestine, Small / drug effects
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / therapeutic use. Tomography, X-Ray Computed. Treatment Failure

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011354.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


22. Solem CA, Harmsen WS, Zinsmeister AR, Loftus EV Jr: Small intestinal adenocarcinoma in Crohn's disease: a case-control study. Inflamm Bowel Dis; 2004 Jan;10(1):32-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small intestinal adenocarcinoma in Crohn's disease: a case-control study.
  • BACKGROUND: Small bowel adenocarcinoma is an uncommon complication of Crohn's disease.
  • We sought to describe the clinical features, outcomes, and risk factors of small bowel adenocarcinoma in Crohn's disease.
  • METHODS: A centralized diagnostic index identified all patients with Crohn's disease with small bowel adenocarcinoma evaluated at our institution between 1976 and 2000, and the medical records were abstracted.
  • Cancer was located in the ileum in 8 patients (89%) and the jejunum in 1 patient (11%).
  • All cases had surgery, with 1 receiving adjuvant chemotherapy.
  • CONCLUSIONS: Small bowel adenocarcinoma is a rare complication of Crohn's disease that typically involves the ileum.
  • [MeSH-major] Adenocarcinoma / epidemiology. Crohn Disease / complications. Ileal Neoplasms / epidemiology. Jejunal Neoplasms / epidemiology


23. Osuagwu CC, Okafor OC, Ezeome ER, Uche CE, Ememonu C, Kesieme E: Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male. Rare Tumors; 2010;2(4):e66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male.
  • This patient presented with partial large bowel obstruction and the pathological analysis revealed 4 invasive adenocarcinomas, 3 in the colon and 1 in the jejunum (Dukes stage D).
  • Palliative pancolectomy and jejunal tumour resection with chemotherapy was offered to him.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Nov 14;14(42):6531-5 [19030207.001]
  • [Cites] East Afr Med J. 1995 Apr;72(4):267-8 [7621765.001]
  • [Cites] West Afr J Med. 2001 Oct-Dec;20(4):251-5 [11885882.001]
  • [Cites] Cent Afr J Med. 1992 Jan;38(1):44-8 [1321689.001]
  • [Cites] Niger J Med. 2005 Apr-Jun;14(2):161-6 [16083239.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cent Afr J Med. 1994 Jan;40(1):8-13 [8082150.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] JOP. 2008;9(1):9-18 [18182737.001]
  • [Cites] Neth J Med. 1989 Jun;34(5-6):317-21 [2549435.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1982-7 [8247073.001]
  • [Cites] Dis Colon Rectum. 1996 May;39(5):536-40 [8620804.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • (PMID = 21234258.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019601
  • [Keywords] NOTNLM ; adenocarcinoma. / colon / familial adenomatous polyposis / jejunum
  •  go-up   go-down


24. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA: Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol; 2010 May;49(4):474-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.
  • BACKGROUND: The benefit of adjuvant therapy for resected small bowel adenocarcinoma has not been proven.
  • We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma.
  • MATERIAL AND METHODS: We identified 54 patients with small bowel adenocarcinoma who underwent margin-negative surgical resection and were evaluated after surgery at the University of Texas, M. D.
  • RESULTS: Median age was 55 years and primary tumor site was duodenum in 67%, jejunum in 20%, and ileum in 13%.
  • Thirty patients (56%) received adjuvant therapy consisting of systemic chemotherapy with or without radiation in 28 and radiation alone in two.
  • Patients who received adjuvant therapy had significantly higher tumor stage and rate of lymph node involvement.
  • Five-year DFS and OS did not differ between treatment groups.
  • In multivariate analysis, the use of adjuvant therapy was associated with improved DFS (HR 0.27; 95% CI 0.07-0.98, P = 0.05) but not OS (HR 0.47; 95% CI 0.13-1.62, P = 0.23).
  • In patients with a high risk of relapse (defined as a lymph node ratio >or=10%), adjuvant therapy appeared to improve OS, P = 0.04, but not DFS, P = 0.15.
  • DISCUSSION: The use of adjuvant therapy for curatively resected small bowel adenocarcinoma was associated with an improvement in DFS.
  • This finding strongly supports further investigation of adjuvant chemotherapy in this tumor type.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / therapy. Intestine, Small
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemotherapy, Adjuvant. Disease-Free Survival. Duodenal Neoplasms / therapy. Female. Follow-Up Studies. Humans. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20397775.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Mizushima T, Sando K, Ito T, Mikata S, Nonaka K, Ide H, Michiura T, Kainuma S, Yamanaka H, Iwase K: [A case of advanced colon cancer responding completely to systemic 5-fluorouracil/l-leucovorin therapy]. Gan To Kagaku Ryoho; 2004 Nov;31(12):2047-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced colon cancer responding completely to systemic 5-fluorouracil/l-leucovorin therapy].
  • Exploratory laparotomy revealed massive direct invasion of the mesenterium of the jejunum for Roux-en Y reconstruction.
  • Systemic chemotherapy with 5-fluorouracil and l-leucovorin was scheduled for a total of 4 courses postoperatively.
  • There was no severe side effect during chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Colostomy. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Neoplasm Invasiveness

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15570938.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Gibson RJ, Bowen JM, Keefe DM: Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer; 2005 Sep 1;116(3):464-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.
  • Mucositis is a common side effect of cancer chemotherapy for which there is currently no treatment.
  • Animals were killed at 6, 24, 48, 72, 96, 120, or 144 hr after treatment.
  • Data were analyzed using Peritz' F-test, Student's t-test and Tukey-Kramer multiple comparison test.
  • Animals pretreated with palifermin tolerated irinotecan treatment better than control animals with less severe diarrhea (5% in animals receiving 10 mg/kg palifermin, 11% in animals receiving 3 x 3 mg/kg palifermin and 28% in animals receiving irinotecan only) and reduced mortality (2% in animals receiving 10 mg/kg palifermin, 11% in animals receiving 3 x 3 mg/kg palifermin and 28% in animals receiving irinotecan only).
  • Intestinal morphometry was not maintained in palifermin-pretreated rats despite being increased prior to irinotecan treatment.
  • Palifermin pretreatment did not prevent apoptosis that peaked at 6 hr in the jejunum or colon, but prevented apoptosis at 96 hr in the small intestine.
  • Palifermin pretreatment in both treatment regimens significantly reduces diarrhea and mortality following irinotecan administration without adversely affecting tumor growth.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Diarrhea / drug therapy. Fibroblast Growth Factors / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / veterinary. Animals. Female. Fibroblast Growth Factor 7. Keratinocytes. Mammary Neoplasms, Animal / drug therapy. Rats. Survival Analysis

  • MedlinePlus Health Information. consumer health - Diarrhea.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800945.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Fgf7 protein, rat; 126469-10-1 / Fibroblast Growth Factor 7; 62031-54-3 / Fibroblast Growth Factors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


27. Polyzos A, Kouraklis G, Giannopoulos A, Bramis J, Delladetsima JK, Sfikakis PP: Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients. J Chemother; 2003 Oct;15(5):503-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients.
  • Small bowel adenocarcinoma (SBA) is a relatively rare disease.
  • Because of its rarity the role of chemotherapy either as adjuvant or for advanced disease has not been clearly defined.
  • We report on three patients with adenocarcinoma of the jejunum and ileum.
  • Two patients with positive lymph nodes received postoperative adjuvant chemotherapy with 5-fluorouracil-folinic acid (5FU-FA) for 12 months but they developed metastatic disease 3 and 8 months later, respectively.
  • All patients were subsequently treated for tumor recurrence with irinotecan 350 mg/m2 i.v. every 3 weeks as salvage chemotherapy supported by Granulocyte Colony Stimulating Factor (GCSF) for 5 days.
  • Their survival times after irinotecan administration were 14 and 6 months with an overall survival after primary diagnosis of 29 and 27 months, respectively.
  • Although conclusions cannot be drawn regarding the role of adjuvant chemotherapy in SBA, it seems reasonable to extrapolate from large bowel carcinoma experience.
  • Irinotecan seems to have some degree of activity in the treatment of SBA but further studies are warranted.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Ileal Neoplasms / drug therapy. Jejunal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Disease Progression. Drug Resistance, Neoplasm. Humans. Male. Salvage Therapy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14598944.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


28. Chen CW, Wang WM, Su YC, Wu JY, Hsieh JS, Wang JY: Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases. Med Princ Pract; 2008;17(6):496-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases.
  • OBJECTIVE: To present our clinical experience of 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen administered as an adjuvant chemotherapy to 2 patients with advanced jejunal adenocarcinoma.
  • A small bowel series as well as the abdominal computed tomography scan revealed an irregular narrowing lesion at the proximal jejunum.
  • The patient then underwent an exploratory laparotomy and the jejunal adenocarcinoma with localized peritoneal metastasis was found (R0 resection, T3N1M1, stage IV).
  • Chemotherapy with FOLFOX4 regimen of 12 cycles was initiated after the curative resection.
  • No adverse event was observed during the period of chemotherapy.
  • Surgical exploration revealed a proximal jejunal adenocarcinoma with regional lymph node involvement (R0 resection, T3N1M0, stage III).
  • She also received the FOLFOX4 chemotherapy of 12 cycles with an uneventful course.
  • No obvious toxicity developed except for temporary grade I peripheral neuropathy and skin eruption.
  • CONCLUSION: This report showed that adjuvant chemotherapy with FOLFOX4 regimen seems effective and well tolerated in these 2 patients with advanced jejunal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Jejunal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Middle Aged. Organoplatinum Compounds / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18836281.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


29. Grundmann RT, Hölscher AH, Bembenek A, Bollschweiler E, Drognitz O, Feuerbach S, Gastinger I, Hermanek P, Hopt UT, Hünerbein M, Illerhaus G, Junginger T, Kraus M, Meining A, Merkel S, Meyer HJ, Mönig SP, Piso P, Roder J, Rödel C, Tannapfel A, Wittekind C, Woeste G: [Diagnosis of and therapy for gastric cancer--work-flow]. Zentralbl Chir; 2009 Aug;134(4):362-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of and therapy for gastric cancer--work-flow].
  • [Transliterated title] Diagnostik und Therapie des Magenkarzinoms--Workflow.
  • AIM: This review comments on the diagnosis and treatment of gastric cancer in the classical meaning--excluding adenocarcinoma of the -oesophagogastric junction.
  • PREOPERATIVE DIAGNOSIS: Besides oesophagogastroduodenoscopy, endoscopic ultrasonography is necessary for the accurate diagnosis of T categories and as a selection criterion for neoadjuvant chemotherapy.
  • Computed tomography is recommended for preoperative evaluation of tumours > T1, laparoscopy has become an effective stag-ing tool in T3 and T4 tumours avoiding unnecessary laparotomies and improving the detection of small -liver and peritoneal metastases.
  • TREATMENT: Endoscopic mucosal resection and submucosal dissection are indicated in superficial cancer confined to the mucosa with special characteristics (T1 a / no ulcer / G1, 2 / Laurén intestinal / L0 / V0 / tumour size < 2 cm).
  • In all other cases total gastrectomy or distal subtotal gastric resection are indicated, the latter in cases of tumours located in the distal two-thirds of the stomach.
  • Standard lymphadenectomy (LAD) is the D2 LAD without distal pancreatectomy and splenectomy.
  • The Roux-en-Y oesophagojejunostomy is still the preferred type of reconstruction.
  • An additional pouch reconstruction should be considered in -patients with favourable prognosis, this also -applies for the preservation of the duodenal passage by jejunum interposition.
  • Perioperative chemotherapy and postoperative chemoradiotherapy are based on the MAGIC and MacDonald trials.
  • Perioperative chemotherapy should be performed in patients with T3 and T4 tumours with the aim to increase the likelihood of curative R0-resection by downsizing the tumour.
  • Adjuvant postoperative chemotherapy cannot be recommended since its benefit has so far not been proven in randomised trials.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart.New York.
  • (PMID = 19688686.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 109
  •  go-up   go-down


30. Milas L, Mason KA, Hunter N, Li C, Wallace S: Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. Int J Radiat Oncol Biol Phys; 2003 Mar 1;55(3):707-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Conjugating drugs with polymeric carriers is one way to improve selective delivery to tumors.
  • Treatment endpoint was TCD(50) (radiation dose yielding tumor control in 50% of mice).
  • Acute radioresponse of jejunum, skin, and hair was determined for all treatments.
  • RESULTS: PG-TXL dramatically improved tumor radioresponse, reducing TCD(50) of single-dose irradiation from 53.9 (52.2-55.5) Gy to 7.5 (4.5-10.7) Gy, an enhancement factor (EF) of 7.2.
  • The drug improved the efficacy of fractionated irradiation even more, reducing the TCD(50) of 66.6 (62.8-90.4) Gy total fractionated dose to only 7.9 (4.3-11.5) Gy, for an EF of 8.4.
  • PG-TXL did not affect normal tissue radioresponse resulting from either single or fractionated irradiation.
  • CONCLUSION: PG-TXL dramatically potentiated tumor radiocurability after single-dose or fractionated irradiation without affecting acute normal tissue injury.
  • To our knowledge, PG-TXL increased the therapeutic ratio of radiotherapy more than that previously reported for other taxanes, thus, PG-TXL has a high potential to improve clinical radiotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Ovarian Neoplasms / radiotherapy. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Polyglutamic Acid / therapeutic use. Radiation-Sensitizing Agents / therapeutic use. Taxoids
  • [MeSH-minor] Animals. Combined Modality Therapy. Confidence Intervals. Dose Fractionation. Dose-Response Relationship, Radiation. Female. Hair / radiation effects. Infusions, Intravenous. Jejunal Diseases / etiology. Mice. Mice, Inbred C3H. Radiation Injuries / etiology. Radiodermatitis / etiology. Radiotherapy Dosage. Specific Pathogen-Free Organisms

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):563-4 [12573741.001]
  • (PMID = 12573758.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-74819
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0 / Taxoids; 0 / paclitaxel poliglumex; 25513-46-6 / Polyglutamic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


31. Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF: Surgically treated primary malignant tumor of small bowel: a clinical analysis. World J Gastroenterol; 2010 Mar 28;16(12):1527-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To evaluate the clinical presentation, treatment and survival of patients with primary malignant tumor of small bowel (PMTSB).
  • Ileum was the most common site of tumor (44.7%), followed by jejunum (30.5%) and duodenum (24.8%).
  • Segmental bowel resection (n = 81) was the most common surgical procedure, followed by right hemi-colectomy (n = 15), pancreaticoduodenectomy (n = 10), and others (n = 19).
  • Twenty-seven adenocarcinoma patients and 13 malignant lymphoma patients received adjuvant chemotherapy with 5-fluorouracil and cyclophosphamide, adriamycin, vincristine and prednisone, respectively.
  • The median survival time of PMTSB patients was 20.3 mo.
  • Adenocarcinoma was found in 73.7% (42/57), 21.1% (12/57) and 15.8% (9/57) of the patients, respectively.
  • CONCLUSION: En bloc resection is the principal therapy for most PMTSB and chemotherapy is the important treatment modality for malignant lymphoma and other malignant tumors of small bowel which cannot be radically removed.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoid Tumor / surgery. Digestive System Surgical Procedures. Gastrointestinal Stromal Tumors / surgery. Intestinal Neoplasms / surgery. Intestine, Small / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):731-41 [15966194.001]
  • [Cites] Cancer Imaging. 2006;6:209-12 [17208678.001]
  • [Cites] World J Gastroenterol. 2007 Jan 21;13(3):432-7 [17230614.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):39-45 [17240306.001]
  • [Cites] Chirurgia (Bucur). 2006 Sep-Oct;101(5):477-81 [17278638.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Mar;19(2):143-9 [17355111.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):229-35 [17372046.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):129-34 [17419246.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2263-9 [17549572.001]
  • [Cites] Arch Surg. 2009 Jul;144(7):670-8 [19620548.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Am J Surg. 2000 Jan;179(1):37-41 [10737576.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):727-32 [11462914.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83 [12153595.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):469-81 [14713260.001]
  • [Cites] Int Surg. 2004 Jan-Mar;89(1):21-6 [15085993.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] AJR Am J Roentgenol. 1989 May;152(5):995-8 [2705358.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1994 Feb;15(1):46-50 [8082141.001]
  • [Cites] Ann Surg Oncol. 1995 Jan;2(1):26-31 [7834450.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1153-8 [9373284.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1440-4 [10424748.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • (PMID = 20333796.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2846261
  •  go-up   go-down


32. Anyanwu SN, Nwofor AM: Primary jejuno-ileal neoplasms in eastern Nigeria. Niger Postgrad Med J; 2003 Mar;10(1):23-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ileum was involved in 5 patients, the jejunum in 4 while 1 showed multiple gut involvement.
  • The rest consisted of lymphosarcoma [5],adenocarcinoma [3] while 1 patient had leiomyo-sarcoma.
  • Treatment offered included resection of small gut in 7 patients and ileo-colectomy in 3 patients.
  • Three patients with lymphosarcoma had a full course of cytotoxic chemotherapy.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12717460.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Nigeria
  •  go-up   go-down


33. Lo YL: Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol; 2000 Nov 1;60(9):1381-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phospholipids have been increasingly used as carriers for the delivery of a variety of drugs.
  • Studies using cancer chemotherapeutic agents such as epirubicin encapsulated in liposomes, which are made of phospholipids and other ingredients, have generally shown reduced toxicity and enhanced therapeutic efficacy.
  • This study investigated the effects of liposomal encapsulation, empty liposome pretreatment, or free lipid pretreatment on the uptake and transport of epirubicin in the human colon adenocarcinoma cell line Caco-2 and in everted gut sacs of rat jejunum and ileum.
  • These two treatments substantially increased apical-to-basolateral absorption of epirubicin across Caco-2 monolayers and markedly improved mucosal-to-serosal absorption of epirubicin in rat jejunum and ileum.
  • In conclusion, the therapeutic efficacy of epirubicin may be improved by using phospholipids as excipients and MDR modulators in the formulations.
  • Liposomal formulations may have important applications to circumvent drug resistance in cancer chemotherapy.
  • [MeSH-major] Drug Resistance, Multiple / physiology. Epirubicin / pharmacology. Intestines / drug effects. Phospholipids / physiology
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / pharmacology. Biological Transport. Caco-2 Cells. Capsules / pharmacology. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Flow Cytometry. Humans. Ileum / drug effects. Ileum / metabolism. Jejunum / drug effects. Jejunum / metabolism. Male. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. EPIRUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11008132.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Capsules; 0 / Phospholipids; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down






Advertisement